文献速递临床生化临床免疫质量管理与危急值

非结合雌三醇(uE3)检测干扰对产前筛查的影响

Impact of Unconjugated estriol (uE3) assay interference on prenatal screening tests.
PubMed 文献 · Clin Chim Acta · 2022-09-09

本研究针对160例既往四联筛查中uE3中位数倍数(MoM)≤0.50的样本,采用添加热灭活碱性磷酸酶(hALP)的试剂策略,评估uE3检测干扰的可扩展识别与缓解方法。结果显示17例样本在添加与未添加hALP的试剂间uE3结果差异>50%,且hALP添加与厂商重构试剂识别出相同的17例干扰样本。模拟计算表明,检测干扰可导致1例21三体和3例18三体的假阳性风险。

要点

  • uE3检测干扰可通过hALP添加策略可扩展地识别和缓解。
  • 160例低uE3(MoM≤0.50)样本中17例存在>50%的结果差异。
  • 检测干扰可导致21三体和18三体筛查的假阳性风险。

核心结论

  • hALP添加策略与厂商重构试剂均能识别相同的17例uE3检测干扰样本,表明该策略可扩展地筛查干扰。
  • 厂商重构试剂解决了抗ALP抗体干扰并改善了筛查性能。

研究设计与样本

  • 研究纳入160例既往四联筛查中uE3 MoM≤0.50的去标识患者样本。
  • 采用试剂添加hALP策略,比较原始批号#920861、添加hALP的#920861及重构批号#922579的uE3检测结果。
  • 以uE3结果差异>50%判定为疑似干扰,并利用测试患者环境计算伪风险。

主要发现

  • 160例样本中17例在添加hALP与未添加hALP的试剂间uE3结果差异>50%。
  • 原始批号#920861添加hALP与重构批号#922579识别出相同的17例干扰样本。
  • 模拟筛查风险显示,检测干扰可导致1例21三体和3例18三体的假阳性风险计算。

关键数值与推荐

  • uE3 MoM≤0.50作为样本入选标准。
  • uE3结果差异>50%定义为疑似干扰。

临床怎么用

  • 对于uE3 MoM偏低(≤0.50)的筛查样本,应考虑检测干扰可能并采用hALP添加或重构试剂进行识别。
  • 厂商重构试剂可减少抗ALP抗体干扰,降低假阳性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Unconjugated estriol (uE3) is an important biomarker in second trimester prenatal screening. Previous studies from our laboratory identified rare interference in the Beckman uE3 assay due to anti-ALP antibodies, which could be mitigated with a scavenger or heat-inactivated ALP (hALP). In the current study, 160 de-identified patient samples previously submitted for the Quad screen with low uE3 multiples of the median (MoM ≤0.50) were investigated for potential interference. METHODS: A reagent pack spiking strategy with hALP was employed to understand if the interference could be identified and mitigated in a scalable manner. The 160 samples were measured using uE3 lot #920861 previously known to be subject to interference, lot #920861 spiked with hALP, and the vendor reformulated lot #922579. Samples were suspected to have interference if the percent difference in uE3 measurements was >50%. Pseudo-risks were calculated using a test patient environment to understand the screening impact due to the change in uE3 result. RESULTS: Seventeen of the 160 samples had uE3 results that were >50% different between the hALP spiked and non-spiked reagent pack. Both original lot #920861 with hALP and reformulated lot #922579 identified the same 17 patients as having interference in lot #920861. Analysis of screening risks using a test patient environment showed that assay interference could result in false positives for one trisomy 21 and three trisomy 18 post-test risk calculations. CONCLUSION: Our experiment of reagent pack spiking with hALP produced similar uE3 results to a reformulated reagent designed to address potential interference, demonstrating that this is a feasible strategy to screen for interference in a scalable manner. The vendor-provided reformulation addressed anti-ALP interference and improved the performance of the screen.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Wyness SP, Snow TM, Villanueva M, et al. Impact of Unconjugated estriol (uE3) assay interference on prenatal screening tests. Clin Chim Acta. 2022. PMID: 36096208. doi:10.1016/j.cca.2022.08.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。